Origin Therapeutics, an investment issuer focused on making equity investments in the psychedelics sector, has completed a CA$6,550,000 ($5.1 million) private placement. <\/p>\n
The firm intends to make investments in private, early-stage psychedelics industry companies. Management told Benzinga it plans to deploy capital across a diverse group of private companies to offer investors exposure to early-stage opportunities with high growth potential.<\/p>\n
Origin Therapeutics will work closely with its portfolio to support the growth of the companies by leveraging its management expertise and professional network.<\/p>\n
The psychedelics sector has such tremendous potential for growth, with the potentially positive impact on mental health being game-changing. Investors want to participate, and while there are a growing number of publicly traded companies doing great work, so much of the innovation is taking place in private companies - and we want to give investors the opportunity to participate in that growth and support it, Alexander Somjen, CEO of Origin Therapeutics, told Benzinga.<\/p>\n
Ms contenido sobre psicodlicos en Espaol en El Planteo.<\/p>\n
Photo: Dasha Yukhymyuk on Unsplash<\/p>\n
See more from Benzinga<\/p>\n
2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n
<\/p>\n
See the original post:<\/p>\n
Origin Therapeutics Will Invest $5.1M In Psychedelics Startups - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Origin Therapeutics, an investment issuer focused on making equity investments in the psychedelics sector, has completed a CA$6,550,000 ($5.1 million) private placement. The firm intends to make investments in private, early-stage psychedelics industry companies Continue reading